DRMA

- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products - - Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to support skin renewal, in the middle of 2026 - - Raised $2.0 million in net proceeds from it's at-the-market ("ATM") financing facility - SAN DIEGO, CA / ACCESS Newswire / May 13, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the first quarter ended March 31, 2026. "Since announcing our strategic pivot in September 2025, we have made meaningful progress toward becoming a direct-to-consumer commercial skincare company," commented Gerry Proehl, Dermata's Chairman, President, and CEO. "This pivot represents a significant landmark in our mission to deliver safe, effective, and consumer-friendly skincare products. We continue to build on that foundation during the first quarter of 2026 by advancing development of our initial product, refining our brand strategy, and aligning our operations to support commercialization. We are currently finalizing product packaging, putting the finishing touches on the Tome skincare website and getting ready to initiate consumer use studies to provide clinical data to support our upcoming product launches," Mr. Proehl continued. "As we look ahead, we remain focused on executing our planned mid-2026 launch of our once-weekly Foundational Treatment for skin renewal that we believe will bring an in-office-like treatment into the hands of consumers. We believe this product launch will position Dermata to deliver long-term value for both consumers and shareholders," concluded Mr. Proehl. Corporate Highlights Announced its new skincare brand, Tome. In March 2026, Dermata revealed its new skincare brand, Tome, which aims to introduce professional skincare at home. The Tome skincare line will emphasize products Dermata believes can become the essential foundation of any well-rounded skincare routine. The Company plans to add multiple products to the Tome skincare portfolio that utilize time-tested remedies to simplify skincare routines, first starting with a once-weekly Foundational Treatment for skin renewal. Announced the hiring of Kyra Peckaitis as Vice President of Market...

- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skincare products under the brand name Tome - - Dermata plans to launch its first DTC product, our Foundational Treatment, a once-weekly mask to support a skin renewal, in the middle of 2026 - - Raised $4.125 million in gross proceeds from a private placement financing in December 2025, including participation from Dermata's Chief Executive Officer, Chief Financial Officer, and a member of the Company's management - SAN DIEGO, CA / ACCESS Newswire / March 26, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the year ended December 31, 2025. "We are extremely excited as we approach the planned launch of our first DTC product in the middle of 2026, as this will be an important milestone in our company's evolution," said Gerry Proehl, Chairman, President, and CEO of Dermata. "Our team has been extremely busy over the past few months since we announced in September 2025 our strategic pivot to sell direct-to-consumer skincare products. Since the announcement, we have recently revealed our new skincare brand, Tome, hired a new Vice President of Marketing to lead the brand, and are close to finalizing the commercial packaging for our first product," Mr. Proehl continued. "We believe we can leverage our deep knowledge from years of clinical dermatology to deliver DTC skincare products that are efficacious and accessible to consumers. With the cash raised from our recent financings, we believe we are in a good financial position for our planned product launches, with potential revenue to follow," concluded Mr. Proehl. Kyra Peckaitis, Dermata's new Vice President of Marketing, commented, "Having recently joined Dermata, I've been incredibly energized by both the strength of the team and opportunity to create something truly differentiated in the skincare market. We are very excited to announce our first product by Tome, our Foundational Treatment, a once-weekly, foundational step designed to renew the appearance of the skin and improve tone and texture over time. Our Foundational Treatment will incorporate our hero ingredient, Spongillalacustris, a wildly harvested freshwater sponge that we call Bioneedle, to pr...

- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments - - Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongilla technology, in the middle of 2026 - SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 14, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the third quarter ended September 30, 2025. "At Dermata, our mission is to bring scientifically developed innovation directly to those who need it most," said Gerry Proehl, Chairman, President, and CEO of Dermata. "Our recent strategic pivot into over-the-counter skincare reflects that same commitment - delivering clinical-grade innovation intended to meet growing consumer demand for accessible, effective, and easy to use dermatologic solutions. The planned launch of our once-weekly acne kit in mid-2026 marks the initial step toward building a scalable portfolio of products that merge medical-grade science with everyday convenience. We see this as more than a product launch - it is the beginning of a new growth chapter where we plan to leverage our deep dermatological know-how, scientific credibility, and innovative Spongilla technology to reach consumers directly. By bridging the gap between prescription care and at-home skincare, we believe we are well positioned to succeed in a rapidly expanding category and drive meaningful long-term value for both patients and shareholders," concluded Mr. Proehl. Corporate Highlights Announced strategic pivot to OTC dermatology company. In September 2025, Dermata announced that it was making a strategic shift from developing prescription dermatology products to developing and launching an OTC pharmaceutical product line to treat multiple skin diseases. The Company is currently working on branding, packaging, and manufacturing to prepare for the expected launch of their first OTC product, a once-weekly acne kit, in the middle of 2026. The Company plans to sell the acne kit directly to consumers, estheticians and dermatologists for in-office treatments. Announced positive topline data from its XYNGARI™ Phase 3 STAR-1 clinical trial in moderate-to-severe acne. In March 2025, Dermata announced that its STAR-1 study met all...

- Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial- - Raised $8.8 million in gross proceeds from a private placement and warrant inducement financings during the first half of 2025 - SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 13, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2025. "We are very excited to have received the full data set from our Phase 3 STAR-1 trial of XYNGARI™ showing that XYNGARI™ achieved statistically significant results for its three co-primary endpoints at weeks 4 and 12," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. "We believe these data show that not only does XYNGARI™ work after the FDA required 12-week primary endpoint, but it also works as early as week four, which was the earliest measured timepoint. We strongly believe if consumers are able to gain access to our Spongilla technology acne patients will experience the many unique benefits our product candidate can offer, and our team continues to work hard to make this happen," concluded Mr. Proehl. Corporate Highlights Announced positive topline data from its XYNGARI™ Phase 3 STAR-1 clinical trial in moderate-to-severe acne. In March 2025, Dermata announced that its STAR-1 study met all three primary endpoints by producing highly statistically significant results versus placebo at the end of study. In April 2025, Dermata also announced that XYNGARI™ achieved statistically significant separation from placebo after just 4 weeks, or only four treatments. STAR-1 is the first of two Phase 3 clinical trials, the second of which would be followed by a long-term extension study, which the Company would need to complete prior to filing a new drug application with the U.S. Food and Drug Administration. Raised $8.8 million in gross proceeds during the first half of 2025. The funds raised during the first half of 2025 are expected to fund its operations into the second quarter of 2026. Anticipated Upcoming Milestones Second XYNGARI™ Phase 3 STAR-2 clinical trial in moderate-to-severe acne. With positi...

- Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints - - Dermata entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 with DAXXIFY® for the treatment of axillary hyperhidrosis - - Raised $8.8 million in gross proceeds from private placement and warrant inducement financings during the first quarter of 2025 - SAN DIEGO, CA / ACCESS Newswire / May 14, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today highlighted recent corporate progress and reported financial results for the first quarter ended March 31, 2025. "It was an exciting quarter for our team to announce positive topline results of the XYNGARI™ Phase 3 STAR-1 trial for the treatment of acne, which achieved statistically significant results of its three co-primary endpoints at all time points," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. "Our team has spent many years working with this product and knew it had strong potential as a treatment for acne and we are happy to see that hard work has paid off with such positive results. We believe the consistent results from our previous clinical studies and this Phase 3 trial derisks the planned second Phase 3 trial and well positions XYNGARI™ to potentially be the first once-weekly, natural, topical treatment for moderate-to-severe acne, if approved. We are also excited to have partnered with Revance to study DMT410 with DAXXIFY® for the topical treatment of axillary hyperhidrosis," continued Mr. Proehl. "We see a lot of potential uses for our DMT410 program and studying it in a Phase 2 study with a long-lasting botulinum toxin, like DAXXIFY®, could provide us with the data needed to show the clinical efficacy of DMT410 aiding in the topical delivery of a botulinum toxin," concluded Mr. Proehl. Corporate Highlights Announced positive topline data from its XYNGARI™ Phase 3 STAR-1 clinical trial in moderate-to-severe acne. In March 2025, Dermata announced that its STAR-1 study met all primary endpoints by producing highly statistically significant results versus placebo at the end of study. In Apri...

- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 - - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics (recently merged with Crown Laboratories) to study DMT410 for the treatment of axillary hyperhidrosis - - Raised $2.55 million in gross proceeds from a private placement financing in January 2025, including participation from Dermata's Chief Executive Officer, Chief Financial Officer, and certain members of the Company's board of directors - SAN DIEGO, CA / ACCESS Newswire / March 17, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today highlighted recent corporate progress and reported financial results for the year ended December 31, 2024. "I am very proud of what our team has accomplished this year, and we are excited to unblind the topline data from our XYNGARI™ Phase 3 STAR-1 trial in the coming weeks," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. "Our team worked hard to make sure the STAR-1 trial was fully enrolled on schedule so we could keep our promise of a planned announcement of topline data in the first quarter of 2025. I am happy to announce that we fully expect to deliver on this promise, with topline results expected to be unblinded and announced by the end of this month. We are also excited to have recently signed a collaboration agreement with Revance to progress our topical botulinum toxin program forward with an approved toxin product, DAXXIFY®. We believe that Revance sees the potential of this program and will be a great partner to study DMT410 in multiple indications such as hyperhidrosis, acne, and rosacea," concluded Mr. Proehl. Corporate Highlights Completed enrollment in its XYNGARI™ Phase 3 STAR-1 clinical trial in moderate-to-severe acne. After completing enrollment in November 2024, Dermata completed the last patient's last visit in March 2025 and expects to announce topline results from the STAR-1 study by the end of March 2025. STAR-1 is the first of two Phase 3 clinical trials, including a long-term extension study, which the Company will need to complete prior to fi...